Research Highlights/News

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2007

»  Look for consumer stories click here

2024

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2025 (FY25)
  December 18, 2024
• Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2024 (FY24)
  January 3, 2024

News:

• New brain-computer interface allows man with ALS to "speak" again (external link)
  UC Davis Health, August 28, 2024
• FDA grants IND clearance for Spinogenix's ALS treatment trial (external link)
  Clinical Trial Arena, June 5, 2024

2023

Press Releases:

• Amyotrophic Lateral Sclerosis Research Program Recognized for Including Consumer Reviewers in Two-Tier Review System
  May 30, 2023

Research Highlights:

• Using Machine Learning for Drug Repurposing to Impact ALS Treatment
• The Therapeutic Potential of Metformin in ALS: Moving Through the ALSRP Pipeline from Therapeutic Development Award (TDA) to Pilot Clinical Trial Award (PCTA)
• New Nerve-on-a-Chip System Could Revolutionize Therapeutic Development for ALS

News:

• Prosetin in ALS patients (external link)
  ALS News Today, December 19, 2023
• USC Stem Cell-led studies point the way to broadly effective treatments for ALS (external link)
  Keck School of Medicine of USC, March 6, 2023

2022

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2023 (FY23)
  December 12, 2022

Research Highlights:

• A Combined Cell and Gene Therapy Approach for Preserving Motor Neuron Function in ALS
• UPDATE: ALS Treatment, Tegoprubart, Advancing Through Clinical Trials
• A New Compound to Prevent Motor Neuron Toxicity in ALS Enters Clinical Trial
• In Vivo Imaging and Novel Therapeutic Approaches in ALS
• A Challenge Best Tackled Together - Bridging the ALS Therapeutic Gap with Industry Partners

News:

• Digital Speech Biomarkers Show Promise in Recording Speech Function, Dysarthria in ALS (external link)
  NeurologyLive, November 15, 2022
• Neurodegenerative disease can progress in newly identified patterns (external link)
  MIT News, October 26, 2022
• Eledon Announces Phase 2a Trial Results of Tegoprubart (AT-1501) - a Drug Invented at ALS TDI (external link)
  PR.com, June 17, 2022
• Funding Supports Continued Development of M102 in Amyotrophic Lateral Sclerosis (external link)
  Aclipse Therapeutics, April 29, 2022

2021

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)
  December 8, 2021

Research Highlights:

• Novel Metabolic Mechanism Implicated in an Early-Onset Form of Amyotrophic Lateral Sclerosis

News:

• AcuraStem's Development Candidate AS-202 Demonstrates Excellent Safety and Potency in Preclinical Models Representing Diverse Forms of ALS (external link)
  AcuraStem, December 16, 2021
• AcuraStem Awarded $1M DOD Grant to Advance AS-202 Drug Development Candidate for ALS (external link)
  AcuraStem, May 27, 2021

2020

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)
  December 22, 2020

Research Highlights:

• Novel ALS therapeutic intervention shows promise in preclinical trials

News:

• New study shows common diabetes drug improves symptoms in genetic form of ALS in mice (external link)
  University of Florida Health, July 23 , 2020

2019

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2020 (FY20)
  December 6, 2019
• Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2019 (FY19)
  October 16, 2018

Research Highlights:

• ALS "Disease in a Dish" Creates Opportunities for Advanced Motor Neuron and Therapeutic Drug Screening
• Amyotrophic Lateral Sclerosis (ALS) Treatment, AT-1501, Enters Clinical Trial

2018

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)
  February 20, 2018

Research Highlights:

• Treatment Spotlight: Q&A with ALSRP Investigator Dr. Sytske Moolenaar

News:

• Genetic cause of ALS and frontotemporal dementia blocked by RNA-binding compound (external link)
  Phys Org, December 31, 2018
• Treeway Announces Promising Data from Phase I Clinical Trial of Lead Program TW001 for ALS (external link)
  Business Wire, June 1, 2018
• ALS Treatment Delays Disease and Extends Life in Rats (external link)
  Cedars-Sinai, April 23, 2018

2017

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2017
  January 23, 2017

News:

• Pimozide Identified as a Potential ALS Therapeutic (external link)
  ALS Association, December 14, 2017
• Dr. John Ravits, ALSRP Programmatic Panel Member, Receives Sheila Essey Award for Research Contributions (external link)
  ALS Association, March 31, 2017

2016

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2016
  January 4, 2016

Research Highlights:

• Targeting miR-155 in Peripheral Monocytes for the Treatment of ALS
• The Petrucelli group creates mice that model the most common cause of ALS and FTD
• Development of Copper ATSM as a Therapeutic for SOD-Familial and Sporadic ALS

News:

• New therapy halts progression of Lou Gehrig's disease in mice (external link)
  Oregon State University, February 12, 2016

2015

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2015
  February 23, 2015

News:

• Nuclear transport problems linked to ALS and FTD ( (external link)
  National Institutes of Health, November 6, 2015

2014

Research Highlights:

• Improving the Effective Bioavailability of ALS Therapeutics
• Designing Pharmacological Agents that Inhibit the Aggregation of SOD1 by Increasing the Net Negative Charge of the Protein

News:

• Toxin from Brain Cell Triggers Neuron Loss in Human ALS Model (external link)
  Columbia University Medical Center, February 21, 2014

2013

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2013
  April 11, 2013

2012

Research Highlights:

• Neuroprotective Small Molecules for the Treatment of Amyotrophic Lateral Sclerosis

News:

• Developing New Compounds to Treat ALS (external link)
  The Scripps Research Institute, October 15, 2012

Video Highlights:

• ALSRP Investigator Highlights

2011

Research Highlights:

• Inhibitors of TDP-43 Aggregation and Toxicity in ALS
• Preclinical Studies of Induced Pluripotent Stem Cell-Derived Astrocyte Transplantation in ALS

News:

• The Chicago ALS Association Newsletter Highlights an ALSRP Consumer Reviewer
  Published: February 9, 2011

2010

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2010
  February 11, 2010

Research Highlights:

• Development of Lead Agents for ALS Treatment in Preclinical Model Systems Based on Differential Gene Expression of IGF-II

2009

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2009
  March 27, 2009

Research Highlights:

• Neuroprotective Small Molecules for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

2007

Press Releases:

• Department of Defense Amyotrophic Lateral Sclerosis Research Program Funding Opportunities for Fiscal Year 2009
  October 15, 2007

Top of Page